Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1976
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 2
1982 2
1983 1
1985 1
1988 6
1989 3
1990 3
1991 7
1992 8
1993 6
1994 7
1995 4
1996 9
1997 6
1998 4
1999 3
2000 12
2001 5
2002 4
2003 8
2004 8
2005 6
2006 5
2007 7
2008 5
2009 6
2010 5
2011 13
2012 7
2013 9
2014 13
2015 14
2016 14
2017 12
2018 7
2019 7
2020 8
2021 6
2022 9
2023 7
2024 7
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

257 results

Results by year

Filters applied: . Clear all
Page 1
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.
Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S. Stacchiotti S, et al. Cancer Treat Rev. 2023 Jan;112:102491. doi: 10.1016/j.ctrv.2022.102491. Epub 2022 Dec 6. Cancer Treat Rev. 2023. PMID: 36502615 Free article. Review.
Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, bursa and tendon sheaths. TGCT comprises a nodular- and a diffuse-type, with the former exhibiting mostly indolent course and
Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints,
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D. Cannarile MA, et al. J Immunother Cancer. 2017 Jul 18;5(1):53. doi: 10.1186/s40425-017-0257-y. J Immunother Cancer. 2017. PMID: 28716061 Free PMC article. Review.
The specificity of these agents and their potent blocking activity has been substantiated by impressive response rates in diffuse-type tenosynovial giant cell tumors, a benign connective tissue disorder driven by CSF1 in an autocrine fashion. .. …
The specificity of these agents and their potent blocking activity has been substantiated by impressive response rates in diffuse- …
Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.
Staals EL, Ferrari S, Donati DM, Palmerini E. Staals EL, et al. Eur J Cancer. 2016 Aug;63:34-40. doi: 10.1016/j.ejca.2016.04.022. Epub 2016 Jun 5. Eur J Cancer. 2016. PMID: 27267143 Review.
At present, the optimal treatment strategy in patients with diffuse-type tenosynovial giant cell tumour (D-TGCT) is unclear. The purpose of this review was to describe current treatment options, and to highlight recent developments in the knowle …
At present, the optimal treatment strategy in patients with diffuse-type tenosynovial giant cell tumour ( …
Diffuse-Type Tenosynovial Giant Cell Tumor An Update of Current Management Strategies.
Naja A, Abboud A, Masrouha K, Ghert M, Saghieh S. Naja A, et al. Bull Hosp Jt Dis (2013). 2024 Sep;82(3):178-185. Bull Hosp Jt Dis (2013). 2024. PMID: 39150871 Review.
Diffuse-type giant cell tumor (Dt-GCT), formerly known as pigmented villonodular synovitis, is the more aggressive entity belonging to the spectrum of benign proliferative lesions of synovial origin that may affect the joint
Diffuse-type giant cell tumor (Dt-GCT), formerly known as pigmented villonodular synovit
Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
Alsayadi YMMA, Chawla PA. Alsayadi YMMA, et al. Anticancer Agents Med Chem. 2021;21(12):1510-1519. doi: 10.2174/1871520620999201102123555. Anticancer Agents Med Chem. 2021. PMID: 33143617 Review.
BACKGROUND: Tenosynovial giant cell tumor refers to a group of rarely occurring tumors that are formed in the joints, which are characterized by pain, swelling, and limitation of movement of the joint. Surgery is the main treatment strategy, but the …
BACKGROUND: Tenosynovial giant cell tumor refers to a group of rarely occurring tumors that are formed in the jo …
Soft Tissue Pathology.
Shane AM, Reeves CL, Nguyen GB, Ferrise TD, Calaj PM. Shane AM, et al. Clin Podiatr Med Surg. 2023 Jul;40(3):381-395. doi: 10.1016/j.cpm.2023.02.003. Epub 2023 Apr 28. Clin Podiatr Med Surg. 2023. PMID: 37236677 Review.
Arthroscopy is frequently used to treat these soft tissue conditions such as instability, synovitis, impingement, arthrofibrosis, and other inflammatory disorders in the rearfoot and ankle. ...
Arthroscopy is frequently used to treat these soft tissue conditions such as instability, synovitis, impingement, arthrofibrosis, and …
Treatment updates on tenosynovial giant cell tumor.
Palmerini E, Staals EL. Palmerini E, et al. Curr Opin Oncol. 2022 Jul 1;34(4):322-327. doi: 10.1097/CCO.0000000000000853. Curr Opin Oncol. 2022. PMID: 35837703 Review.
PURPOSE OF REVIEW: Diffuse-type tenosynovial giant cell tumor (dt-TGCT) is a benign clonal neoplastic proliferation arising from the synovium. ...RECENT FINDINGS: TGCT cells overexpress colony-stimulating factor 1 (CSF1), resulting in rec …
PURPOSE OF REVIEW: Diffuse-type tenosynovial giant cell tumor (dt-TGCT) is a benign clonal neoplas …
Pigmented villonodular synovitis/giant cell tumor in the knee.
Chipman DE, Perkins CA, Lijesen E, Green DW. Chipman DE, et al. Curr Opin Pediatr. 2024 Feb 1;36(1):78-82. doi: 10.1097/MOP.0000000000001312. Epub 2023 Nov 23. Curr Opin Pediatr. 2024. PMID: 37994651 Review.
PURPOSE OF REVIEW: Pigmented villonodular synovitis (PVNS) is a rare diagnosis in pediatric patients and commonly presents with symptoms of swelling and pain. ...
PURPOSE OF REVIEW: Pigmented villonodular synovitis (PVNS) is a rare diagnosis in pediatric patients and commonly prese …
Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
Ravi V, Wang WL, Lewis VO. Ravi V, et al. Curr Opin Oncol. 2011 Jul;23(4):361-6. doi: 10.1097/CCO.0b013e328347e1e3. Curr Opin Oncol. 2011. PMID: 21577109 Review.
PURPOSE OF REVIEW: To review recent developments in the molecular pathogenesis of tenosynovial giant cell tumor (TGCT) or pigmented villonodular synovitis (PVNS) and its therapeutic implications. ...Recurrences occur in 8-20% of pa …
PURPOSE OF REVIEW: To review recent developments in the molecular pathogenesis of tenosynovial giant cell tumor
Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence.
Martin RC 2nd, Osborne DL, Edwards MJ, Wrightson W, McMasters KM. Martin RC 2nd, et al. Oncol Rep. 2000 Mar-Apr;7(2):413-9. Oncol Rep. 2000. PMID: 10671695 Review.
Giant cell tumor of the tendon sheath (GCTTS), tenosynovial giant cell tumor (TGCT), and pigmented villo-nodular synovitis (PVNS) are the common names for a group of rare proliferative disorders that involve synovial
Giant cell tumor of the tendon sheath (GCTTS), tenosynovial giant cell tumor (TGCT), and
257 results